Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2024 07:00 ET | Source: Artios Pharma, Inc.

Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD

CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug...
February 07, 2024 08:00 ET | Source: Artios Pharma, Inc.

Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer

CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug...
October 23, 2023 08:00 ET | Source: Artios Pharma, Inc.

Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

Molecular and clinical responses observed across multiple cancer types, including those with high replication stress Predictable and manageable safety profile with reliable pharmacokinetics offers...
October 05, 2023 08:00 ET | Source: Artios Pharma, Inc.

Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replication stress tumors Phase 1 dose escalation data...
February 09, 2023 08:00 ET | Source: Artios Pharma, Inc.

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer

ART0380 demonstrated a tolerable and manageable safety profile, with monotherapy clinical activity in tumors predicted to be sensitive to ATR inhibition in Phase 1 dose escalationFirst of three Phase...
August 10, 2022 03:00 ET | Source: Artios Pharma, Inc.

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

ART4215 is a potentially first-in-class, highly selective, oral small molecule inhibitor targeting the Polθ polymerase domainInterim Phase 1 tolerability and pharmacokinetic data supports a...
June 23, 2022 08:00 ET | Source: Artios Pharma, Inc.

Artios Appoints Samantha Truex to Board of Directors

CAMBRIDGE, United Kingdom and NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company pioneering the development of novel small molecule...
April 05, 2022 03:00 ET | Source: Artios Pharma, Inc.

Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation

Phase 1a dose escalation of ART0380 defined initial regimen to be evaluated in Phase 1b setting.Phase 1a dose escalation demonstrated a predictable safety profile and no unexpected safety findings...
November 16, 2021 03:00 ET | Source: Artios Pharma, Inc.

Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair

CAMBRIDGE, United Kingdom and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a leading biotech company pioneering the development of novel small molecule therapeutics...
September 28, 2021 03:00 ET | Source: Artios Pharma, Inc.

Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215

Polθ inhibitor, ART4215, is the first selective, orally bioavailable, small molecule inhibitor of the Polθ polymerase domain to enter the clinicPhase 1/2a study evaluating Polθ inhibitor, ART4215, in...